Liaoning Chengda Biotechnology Co.,Ltd. (SHA:688739)
China
· Delayed Price · Currency is CNY 23.26
-0.57 (-2.39%)
At close: Apr 29, 2026
SHA:688739 Revenue
In the year 2025, Liaoning Chengda Biotechnology had annual revenue of 1.39B CNY, down -17.06%. Liaoning Chengda Biotechnology had revenue of 294.40M in the quarter ending December 31, 2025, a decrease of -21.19%.
Revenue
1.39B
Revenue Growth
-17.06%
P/S Ratio
6.88
Revenue / Employee
769.39K
Employees
1,788
Market Cap
9.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.39B | -285.95M | -17.06% |
| Dec 31, 2024 | 1.68B | -73.86M | -4.22% |
| Dec 31, 2023 | 1.75B | -64.90M | -3.58% |
| Dec 31, 2022 | 1.81B | -273.04M | -13.08% |
| Dec 31, 2021 | 2.09B | 92.47M | 4.63% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Jan 1, 2019 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Beijing Hotgen Biotech | 404.88M |
| Aurisco Pharmaceutical | 1.68B |
| Bio-Thera Solutions | 935.22M |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 1.94B |
| Shanghai Medicilon | 1.16B |
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 1.84B |
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 15.90B |
| HitGen | 525.57M |